AI Medical Service is one of the world's first real-time endoscopic artificial intelligence (AI) developers that helps detect gastric cancer.
AI Medical's mission is to develop a system that supports endoscopist’s diagnosis for digestive tract including esophagus, stomach, and intestines.
AI Medical Service was founded in 2017 by Tomohiro Tada and is based in Toshima-ku, Tokyo, Japan.
AI Medical develops AI technology that brings together the wisdom of Japanese endoscopic specialists and supports endoscopic examinations of gastrointestinal organs, such as the esophagus, stomach, small intestine and large intestine.
AIM, by bringing endoscopic AI to real-world clinical setting as soon as possible, aims to reduce the number of missed cancer diagnoses and save lives around the world.
AIM is engaging in joint research with more than 100 medical institutions with the aim of bringing endoscopic AI to real-world clinical setting as soon as possible to reduce the number of missed cancer diagnoses and save lives.
AIM is backed by SoftBank Vision Fund 2, Globis Capital Partners, World Innovation Lab (WiL), Sony Innovation Fund by IGV, Incubate Fund, and others. The company raised 8 Billion JPY ($70M) in Series C roundd on Apr 26, 2022. This brings AIM's total funding to $127M to date.